A 25-year-old man with a genetic disorder presents for genetic counseling because he is concerned about the risk that any children he has will have the same disease as himself. Specifically, since childhood he has had difficulty breathing requiring bronchodilators, inhaled corticosteroids, and chest physiotherapy. He has also had diarrhea and malabsorption requiring enzyme replacement therapy. If his wife comes from a population where 1 in 10,000 people are affected by this same disorder, which of the following best represents the likelihood a child would be affected as well?
A0.01%
B2%
C0.5%
D1%
E50%
A 68-year-old man is being evaluated in your radiation oncology clinic for treatment of a solid tumor. Your hospital has just purchased a new proton beam purported to deliver targeted radiation with fewer side effects than traditional radiation therapy. The patient expresses strong interest in receiving proton beam therapy, and you feel that he may have a better outcome with this new treatment modality. Later that day, an executive from the patient's insurance company calls to tell you that proton beam therapy will cost the company (but not the patient) a much larger amount of money than traditional therapy. They are willing to pay for proton beam therapy, but request that you convince the patient to undergo traditional therapy instead. You have a longstanding relationship with this insurance company as well as this particular executive. How should you proceed?
ATell the patient that proton beam therapy will not be covered by his insurance company, so you will need to proceed with traditional radiation therapy
BDiscuss the issue of cost to the insurer with your patient, relaying the company's request to him without making further commentary or recommendation
CCall your hospital's ethics committee for a formal consultation
DProceed with proton beam therapy as discussed at your patient's appointment
EDiscuss the issue of cost to the insurer with your patient, pointing out that keeping his insurance company happy may make them more likely to cover additional treatments in the future
A new treatment for hemorrhagic stroke, which is a life-threatening clinical condition that occurs when a diseased blood vessel in the brain ruptures or leaks, was evaluated as soon as it hit the market by an international group of neurology specialists. In those treated with the new drug, a good outcome was achieved in 30%, while those treated with the current standard of care had a good outcome in just 10% of cases. The clinicians involved in this cohort study concluded that the newer drug is more effective and prompted for urgent changes in the guidelines addressing hemorrhagic stroke incidents. According to the aforementioned percentages, how many patients must be treated with the new drug to see 1 additional good outcome?
A5
B30
C20
D15
E10
+ 7 more in the PDF
Browse all chapters